allogeneic donor derived B-lymphocytes

Allogeneic donor derived B-lymphocytes is a cellular therapy that involves the collection and infusion of B cells from an allogeneic donor (typically the same donor who provided hematopoietic stem cells for transplantation) to a transplant recipient. This therapy is being investigated to enhance immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapy works by transferring mature, functional B cells from the donor to the recipient, which may help improve antibody responses and reduce the risk of infections during the post-transplant period when the patient's immune system is compromised. According to the search results, these B cells are prepared using GMP (Good Manufacturing Practice) protocols, typically involving a two-step magnetic cell separation process from donor apheresis products[5]. A phase 1/2a clinical trial has been conducted to evaluate the safety and efficacy of this approach. The trial showed that transferred donor B cells can enhance memory antibody responses to vaccine antigens, with patients receiving higher B-cell doses showing stronger responses. Analysis of immunoglobulin sequences revealed that plasmablasts responding to vaccination originated from memory B-cell clones from the donor[5]. The therapy appears to be safe, with no significant Epstein-Barr virus (EBV) reactivation observed, and only low-grade graft-versus-host disease (GVHD) occurring in a minority of patients (4 out of 15 in the reported trial)[5]. This approach represents a novel form of adoptive immunotherapy that specifically targets B-cell immunity, complementing other approaches like donor lymphocyte infusion (DLI) which primarily involves T cells and targets the graft-versus-leukemia effect.